The material contained on this Web site is provided for informational purposes only and does not constitute legal advice. The publication and receipt of any information contained on this Web site does not create an attorney-client relationship with Barash Law LLC or with any of our attorneys. Readers should not act upon any information on this site without seeking professional legal counsel. While the information on this Web site is maintained and periodically updated for accuracy, this information may contain omissions or errors for which we disclaim any and all liability.
Barash Law LLC does not collect identifying information from visitors to its Web site unless the information is provided by the visitor or the visitor's internet browser. We will only respond to direct inquiries, and will use information collected from internet browsers for the sole purpose of monitoring Web site usage. We do not share Web site data with outside third-parties. Barash Law LLC is not responsible for the privacy practices or content of any links to other Web sites contained in our Firm’s Web site.
If you have any questions or concerns regarding this Privacy Statement, please contact us at email@example.com
Moving in the Right Direction: Cocrystals and the FDARead More
Using Solid Form Patents to Protect Pharmaceutical Products — Part IRead More
Using Solid Form Patents to Protect Pharmaceutical Products — Part IIRead More
IP Watchdog Webinar on Pharmaceutical Salts - Part II
April 28th, 2022
Eyal Barash will be speaking in a panel discussion alongside Dr. Stephen Byrn of Purdue University, Dr. Steven Zeman of Grunecker Patent Attorneys and Gene Quinn of IPWatchdog. This webinar will focus on questions related to obviousness and inventive step, enablement, written description sufficiency, and scientific aspects of pharmaceutical salts. This webinar is a follow-up to the presentation ‘Pharmaceutical Salts and other Complexes – A Solid Form Strategy’ from March 1st. Many of the questions raised by the audience during that webinar will be specifically addressed by the panel in this sequel.Watch the Webinar Here!
CTL@WCM Special Panel on Drug Repurposing
MAY 24th, 2022
Can you teach an old drug a new trick? Recent successes in repositioning existing drugs – from esketamine for treatment-resistant depression to remdesivir – originally developed to treat hepatitis C, tested for Ebola before being approved as a treatment for COVID 19 – point to potential upsides. The challenges, however, are many: from challenging IP prospects to skeptical investors. We have assembled an expert panel to discuss with us the enticing shortcuts repurposing may offer, the pitfalls it brings and how to develop strategies to overcome them.
Join us at the second virtual CTL@WCM Special Panel, where innovators, IP experts, and regulators gather to assess the landscape and talk about the opportunities.
What is a solid form?
A solid form is the solid
representation of a chemical compound. Examples
include polymorphs, salts, solvates, hydrates, cocrystals, and amorphous
Why patent solid forms?
Solid forms are
compositions of matter and Orange-Book listable as drug substance. When the science is right, patenting follows.
How do you patent a solid form?
The same rules apply to
solid forms as to any other inventions.
Careful attention should be paid to the kinds and quality of data used
in solid form patents.
Orange-Book Listable Patents Add Value
Intellectual Property as
ip strategy and execution
A Strategy Requires a
Legal Functionality as a
This is some text inside of a div block.